

GENNEX LABORATORIES LIMITED
REGD. OFF: SURVEY NO. 133, BOLLARAM, JINNARAM MANDAL, MEDAK DIST - 502 325
Statement of Audited Results for the Quarter and Year Ended 31st March, 2016

PART I		(Rs. in lakhs)				
Sl. No.	Particulars	Quarter Ended			Year Ended	
		31.03.2016	31.12.2015	31.03.2015	31.03.2016	31.03.2015
1	Income from Operations	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Audited)
	Sales/Income from Operations	1049.86	955.14	960.62	4031.24	3332.47
	Less: Excise Duty	54.96	47.50	36.31	178.03	146.10
a	Net Sales/Income from Operations	994.90	907.64	924.31	3853.21	3186.37
b	(b) Other operating Income	0.39	0.55	0.88	2.39	3.33
	Total Income from operations (net)	995.29	908.19	925.19	3855.60	3189.70
2	Expenses					
	(a) Cost of material consumed	630.66	483.28	518.23	2358.37	1955.24
	(b) Purchases of stock-in-trade	0.00	0.00	22.90	65.78	73.50
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-96.82	39.52	68.40	-161.06	9.25
	(d) Employee benefit expense	118.75	102.92	93.49	411.56	336.23
	(e) Depreciation and amortisation expense	19.64	21.43	20.38	83.60	88.61
	(f) Other expenses	218.29	164.76	168.56	761.28	613.10
	Total expenses	890.52	811.91	891.96	3519.53	3075.93
3	Profit(+)/Loss(-) from operations before other income, finance costs and exceptional items (1-2)	104.77	96.28	33.23	336.07	113.77
4	Other income	5.09	7.33	3.00	21.43	18.57
5	Profit(+)/Loss(-) from ordinary activities before finance costs and exceptional items (3+4)	109.86	103.61	36.23	357.50	132.34
6	Finance costs	13.85	11.87	20.70	50.38	47.63
7	Profit(+)/Loss(-) from ordinary activities before exceptional items (5-6)	96.01	91.74	15.53	307.12	84.71
8	Exceptional items	1.15	0	0	-3.78	0
9	Profit(+)/Loss(-) from ordinary activities before tax (7+8)	97.16	91.74	15.53	303.34	84.71
10	Tax expense	69.24	0	14.80	69.65	19.30
11	Profit(+)/Loss(-) from ordinary activities after tax (9-10)	27.92	91.74	0.73	233.69	65.41
12	Extraordinary items (net of tax expense Rs. Lakhs)	0	0	0	0	0
13	Net Profit(+)/Loss(-) for the period (11+12)	27.92	91.74	0.73	233.69	65.41
14	Paid-up Equity Share Capital (Face value Rs. 1 each Equity Share)	1265.03	1265.03	1265.03	1265.03	1265.03
15	Reserve excluding Revaluation Reserves				1558.66	1287.55
16. i	Earning Per Share (before extraordinary items) (of Rs. 1 each) (not annualised) :					
	(a) Basic	0.022	0.073	0.001	0.185	0.052
	(b) Diluted	0.022	0.073	0.001	0.185	0.052
16. ii	Earning Per Share (after extraordinary items) (of Rs. 1 each) (not annualised) :					
	(a) Basic	0.022	0.073	0.001	0.185	0.052
	(b) Diluted	0.022	0.073	0.001	0.185	0.052

Standalone Statement of assets and liabilities.

(Rs. In Lakhs)

Particulars	31-03-2016		31-03-2015
A) EQUITY AND LIABILITIES	Audited		Audited
1 Shareholders' Funds:			
a) Share Capital	1265.03		1265.03
b) Reserves and Surplus	1558.65		1287.55
	2823.68		2552.58
2 Non - Current Liabilities			
a) Long-term borrowings			
- Secured	3.05		21.83
- Unsecured	11.72		15.97
b) Deferred Tax Adjustment	98.31		77.59
c) Long-term provisions	0		0
	113.08		115.39
3 Current Liabilities			
a) Short-term borrowings			
- Secured	223.79		339.55
- Unsecured	4.25		6.90
b) Trade payables	704.65		675.61
c) Others current liabilities	233.88		184.94
d) short-term provisions	75.78		45.46
TOTAL	1242.35		1252.46
GRAND TOTAL (1+2+3)	4179.11		3920.43
B) ASSETS			
1 Non-Current Assets			
a) Fixed Assets			
i) Tangible Assets	1557.92		1470.20
ii) Intangible Assets	0.00		0.00
b) Non-Current Investments	701.00		701.00
c) Other non-current assets	23.97		18.24
	2282.89		2189.44
2 Current Assets			
a) Inventories	294.20		126.79
b) trade receivable	695.93		619.03
c) Cash and Cash equivalents	84.78		55.65
d) Short-term loans and Advances	817.38		927.09
e) Other current assets	3.93		2.43
TOTAL	1896.22		1730.99
GRAND TOTAL (1+2)	4179.11		3920.43

NOTES:

- 1) The above audited results for the quarter and year ended March 31,2016 have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on May 30, 2016.
- 2) Tax Expenses include Current Tax and Deferred tax.
- 3) The major operations of the company relate to only one segment viz., Bulk Drugs, Biotech Products & Intermediates. As such there is no separate reportable segment under Accounting Standard 17 of Segment Reporting.
- 4) Previous period's figures have been regrouped / rearranged wherever considered necessary.

Place: Hyderabad

Date: 30.05.2016

For and on behalf of the Board
For Gennex Laboratories Limited

Sd/-
Arihant Baid
(Managing Director)